Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function
Recruiting now · Phase 1
Conditions studied: Chronic Hepatitis B Infection
In brief
This is a Phase 1 non-randomized, open-label, single-dose study of pevifoscorvir sodium (also known as ALG-000184) in participants with severe renal impairment (Part 1), in participants with mild or moderate renal impairment (Optional Part 2) and in participants without renal impairment (Parts 1 and 2), matched for age, body weight and, to the extent possible, for sex.
Key facts
- Study ID
- NCT07342881
- Run by
- Aligos Therapeutics
- People needed
- 30
- Starts
- 2026-02-20
- Expected to finish
- 2026-07-01
- Last updated by the study team
- 2026-02-27
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: accepted.
Where it is running
- Orlando Clinical Research Center — Orlando, Florida, United States (enrolling)
- Genesis Clinical Trials — Tampa, Florida, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.